A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS) by Rathbone, J. et al.
A systematic review of eculizumab
for atypical haemolytic uraemic
syndrome (aHUS)
John Rathbone,1 Eva Kaltenthaler,1 Anna Richards,2 Paul Tappenden,1
Alice Bessey,1 Anna Cantrell1
To cite: Rathbone J,
Kaltenthaler E, Richards A,
et al. A systematic review of
eculizumab for atypical
haemolytic uraemic
syndrome (aHUS). BMJ Open
2013;3:e003573.
doi:10.1136/bmjopen-2013-
003573
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-003573).
Received 10 July 2013
Revised 5 September 2013
Accepted 4 October 2013
1School of Health and
Related Research, University
of Sheffield, Sheffield, UK
2Centre for Complement &
Inflammation Research,
Imperial College, London, UK
Correspondence to
Dr Eva Kaltenthaler;
e.kaltenthaler@sheffield.ac.uk
ABSTRACT
Objective: To determine the efficacy and safety of
eculizumab for patients with atypical haemolytic
uraemic syndrome (aHUS), compared with current
treatment options.
Design: A systematic review was performed according
to the general principles of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement. All study designs were included,
except case histories.
Participants: All patients diagnosed with aHUS were
included; no age restrictions were used.
Interventions: Eculizumab compared with current
treatment options.
Identification of studies: 12 databases were
searched. Additional searches were performed through the
Food and Drug Administration (FDA) and the Electronic
Medicines Compendium websites, Google internet
searches and contacting clinical experts. Reference lists of
relevant articles were checked for additional studies.
Results: 2 small, uncontrolled prospective multinational,
multicentre studies and one small uncontrolled
multinational, multicentre retrospective study were
included. No meta-analyses were performed. Compared
with baseline measures, thrombotic microangiopathy
event-free status was achieved in 84% of patients in the
prospective studies. Adverse events, as documented by
enrolling investigators were frequent, with upper-
respiratory tract infection affecting a third of patients. No
deaths or episodes of meningitis or meningococcal
septicaemia occurred in the prospective studies. Results
of the study extension phases up to 114 weeks indicate
that the benefits of the treatment are sustained.
Conclusions: Eculizumab is clinically effective for the
treatment of aHUS. Further research is needed to evaluate
eculizumab, ideally using patient-related clinical
outcomes. If randomised studies are not feasible, study
investigators should ensure that the threat of bias is
minimised in future studies of eculizumab with respect to
the reporting of patient recruitment and selection.
INTRODUCTION
Haemolytic uraemic syndrome (HUS) is
deﬁned as an acute onset of renal impair-
ment with increased serum urea and
creatinine levels, thrombocytopenia (platelet
count <150×109/L) and microangiopathic
haemolytic anaemia (haemoglobin <10 g/
dL).1 2 It is most usefully classiﬁed according
to the underlying aetiology.3 The commonest
cause of HUS (90%) is Shiga toxin-mediated
HUS (Stx-HUS), historically deﬁned as
‘typical HUS’. A second type of HUS, known
as atypical HUS (aHUS) is aetiologically dis-
tinct and may be familial (20%) or sporadic
(80%).4 aHUS is classed as a rare or ultra-
orphan disease, which in the UK describes
conditions with a prevalence of <1 case/
50 000 population.5 There are approximately
170 people with aHUS in the UK. The
European community data estimate the inci-
dence of aHUS to be 2 per million popula-
tion and prevalence as 7 cases per million in
children.6 Recent data have shown that the
onset of aHUS is as frequent in adulthood
(58.4%) as in childhood (41.6%). Seventy
per cent of all cases studied (n=214) had pre-
sented by 40 years of age.7
aHUS commonly develops due to dysregu-
lation of the alternative pathway of comple-
ment. To date, mutations in the complement
regulatory genes factor H (CFH, 20–30%),
membrane cofactor protein (CD46, 10–
15%), factor I (CFI, 5–10%) and
Thrombomodulin (THBD, 3–5%); the activa-
tory genes factor B (CFB, 1–4%) and C3 (2–
10%) and autoantibodies to CFH (6–10%)
Strengths and limitations of this study
▪ Follow-up data at 2 years indicate that benefits of
treatment are sustained.
▪ Adverse events were frequent, although no
severe life-threatening adverse events were asso-
ciated with treatment.
▪ The small number of patients included in these
uncontrolled studies and the use of surrogate
markers is a limiting factor and the inference of
treatment effects may be confounded.
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have been described and account for 50–60% of aetio-
logically deﬁned aHUS.4 8 Mutations causing an
aHUS-like phenotype are also reported in non-
complement pathway genes, for example, in MMACHC9
and MTRR10 genes of the cobalamin pathway and the
lipid kinase diacylglycerol kinase epsilon (DGKE) gene.11
The natural history of aHUS relates to the underlying
genetic mutation, and historically it has been a condi-
tion with a poor prognosis. More than 60% of patients
with mutations in CFH, CFI, C3, FB or THBD die or
develop end-stage renal disease (ESRD) or death despite
active treatment within 1 year of presentation.12 Patients
with CD46 mutations have a better long-term outcome,
with 30% progressing to ESRD, despite a frequently
relapsing course.13 The mortality rate is higher in chil-
dren than in adults (6.7% vs 0.8% at 1 year, p=0.02), but
progression to ESRD was more frequent in adults (46%
vs 16%, p<0.001).7
Evaluating a role for eculizumab in the management
of aHUS requires an assessment of previous best prac-
tice. In addition to supportive care and dialysis, the
mainstay of treatment for acute or relapsing episodes of
aHUS was plasma infusion (PI) or plasma exchange
(PE) therapy. Outcomes of plasmapheresis for aHUS
have recently been reviewed4 14; although around 60%
of patients with aHUS respond initially,15 historical
reports suggest that 50% are left with chronic kidney
injury.16 In those with factor H autoantibody aHUS, the
antibody titre often rises after plasmapheresis is discon-
tinued and aHUS recurs. The chance of relapses may be
signiﬁcantly reduced by the addition of an immunosup-
pressive therapy. The choice of agent is not currently
standardised but has included steroids, mycophenolate
mofetil, cyclophosphamide and rituximab.4
Overall, plasmapheresis is a safe procedure with a mor-
tality rate of less than 1 in 10 000 PE procedures.14 17
Potential complications include risks associated with vas-
cular access insertion, infection; ﬂuid balance changes
during the procedure; hypersensitivity reactions; a small
risk of viral transmission from plasma; and reduced
patient tolerance over the longer term leading to treat-
ment withdrawal.14 18 Plasmapheresis in children has
recently been reviewed. It can be performed safely but
has additional technical challenges. There are high rates
of catheter-related thrombosis and infection and a need
to modify treatments to avoid complications from the
relatively large extracorporeal blood volumes needed to
use the automated apheresis equipment.19
For those with end-stage kidney disease on long-term
dialysis, options have been very restrictive. This is
because isolated renal transplantation in those with
soluble protein mutations in, for example, factor H or
factor I, is associated with extremely high rates of graft
loss due to the recurrence of aHUS. As such, isolated
renal transplantation cannot normally be recom-
mended.20 Attempts to overcome this issue included a
small number of reports of renal transplantation with
the addition of long-term PE15 or use of combined
liver–kidney transplantation.21 Liver–kidney transplant-
ation has been successful, but has a signiﬁcant proced-
ural morbidity rate and risk of death. There is a clear
need for the development of alternative therapeutic
strategies in aHUS for primary treatment and to facili-
tate renal transplantation.
A previous systematic review of HUS interventions (lit-
erature included up to June 2006), was published in
2009. Seven randomised controlled trials (RCTs) in 476
young children, who predominantly had Stx-HUS were
included. There were many limitations, of which the
small number of participants with aHUS and the failure
of ﬁve of the seven trials to recruit and to report results
for atypical and typical HUS separately are of particular
relevance to this work. None of the interventions
studied were superior to supportive therapy in patients
with Stx-HUS.2 No RCTs speciﬁcally evaluating the
effectiveness of any intervention including PE or PI were
found for patients with aHUS.2
Eculizumab is a new therapy being tested in patients
with aHUS. Eculizumab (Soliris) is a humanised mono-
clonal IgG2/4κ antibody produced from murine
myeloma cells by recombinant DNA technology. It acts
as a complement inhibitor, binding speciﬁcally to com-
plement protein C5 with high afﬁnity, thereby inhibiting
cleavage to C5a, a prothrombotic and proinﬂammatory
molecule and C5b, preventing the generation of the ter-
minal complement complex C5b-9.22 It was originally
tested for rheumatoid arthritis without success, but is
now used routinely for paroxysmal nocturnal haemo-
globinuria (PNH).23 It is licensed by the European
Medicines Agency (EMA), and the US Food and Drug
Administration (FDA) for treatment of aHUS.24 The
drug is not yet widely available in the UK.
METHODS
We undertook a systematic review with the aim of asses-
sing the evidence for the efﬁcacy and safety of eculizu-
mab for patients with aHUS, compared against current
treatment options. A protocol was developed and a sys-
tematic review performed according to the general prin-
ciples recommended in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement.25
Inclusion criteria
Studies were included if patients had a diagnosis of
aHUS (no age restrictions were used) and received ecu-
lizumab. Relevant comparators were PI, PE, dialysis and
renal transplantation. All study designs were included,
except case histories.
Identification of studies
We sought relevant studies by searching the following
databases: MEDLINE (1966 to January 2012), EMBASE
(1980 to January 2012), MEDLINE In-Process ( January
2012), Biological Abstracts (1985 to January 2012), NHS
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EED ( January 2012), NHS HTA ( January 2012), Web of
Science (1899 to December 2010), CENTRAL/CCTR
( January 2012), CDSR ( January 2012), CINAHL (1982
to January 2012), Citation Indexes (Science and Social
Sciences; January 2012), DARE ( January 2012).
Ongoing trials were sought using ClinicalTrials.gov,
Current Controlled Trials and UKCRN Portfolio data-
base. For grey literature, OpenGrey database was
searched. Authors were contacted for additional data
and searches of the US FDA and Electronic Medicines
Compendium websites were also undertaken to obtain
further data. An update search was undertaken in June
2013. The search strategy was designed to identify all
studies with no language restriction (see online supple-
ment 1).
Study selection and data extraction
Titles and abstracts were independently screened for
relevance by two reviewers ( JR and EK) and full text
reports of potentially relevant studies were inspected for
inclusion. Where disagreements occurred, resolution
was achieved by discussion and where doubt remained, a
third reviewer was consulted. Data were abstracted by
two reviewers ( JR and EK), quality assessed and cross-
checked for accuracy.
Assessment of study quality
The prospective studies identiﬁed by the search were
appraised using checklist criteria for non-randomised
studies adapted from Chambers.26 The quality of the
retrospective study was not assessed due to the inherent
biases associated with this study design and the lack of a
control group.
RESULTS
Study selection
The database search identiﬁed 1398 citations. Nine
further citations were identiﬁed from additional
searches from other sources. Once duplicates were
removed, 1218 citations were excluded at the title/
abstract stage and 189 articles were obtained for examin-
ation of the full text. Of these, 176 were excluded
because they did not meet the inclusion criteria. In
total, three studies were identiﬁed from the searches,
relating to 13 citations (PRISMA diagram, see online
supplement 2).
Study characteristics
Of the three studies, two were prospective, open-label,
single-arm studies (C08-00227–34 and C08-00333–36). Study
C08-002 (trial 137) included patients in the early phase of
aHUS who were resistant to plasma therapy, while patients
in C08-003 (trial 237) had longer term aHUS and were
receiving maintenance plasma therapy. The third study
was a retrospective single arm study (C09–001R38 39) with
15 paediatric patients. Details of the study characteristics
are shown in online supplement 3.
Risk of bias assessment
A summary of the risk of bias in studies C08-002 and
C08-003 is presented in online supplement 4. Bias was
assessed using a modiﬁed assessment criteria for case
series.26 The quality of study C09-001R was not assessed
due to the inherent biases associated with retrospective
study designs.
Selection criteria were reported in both studies, but
patient eligibility was not clearly described. It is unclear
how patients were selected or whether all patients identi-
ﬁed with aHUS who ﬁtted the inclusion criteria were
included in the studies. It is unclear whether study
populations derived from multiple multinational special-
ist centres can be considered representative of patients
with aHUS seen in routine clinical practice. Both studies
restricted the population to include only patients with
age >12 years.
Appropriate measures of variability were used in both
studies, with CIs reported around the points estimate to
indicate variability. Loss to follow-up and reasons for
leaving the studies early were reported in both studies,
and more than 90% of those included at baseline were
followed up. It is not clear from the study reports
whether patients were recruited prospectively. Patients
were not recruited consecutively which introduces
potential for recruitment bias. Prognostic factors such as
complement abnormalities and biochemical tests were
reported for both studies.
Results of individual studies
Table 1 shows the main efﬁcacy results for the two pro-
spective studies. In both prospective studies, change in
platelet count from baseline to week 26 was signiﬁcantly
different at the 95% conﬁdence level. In study C08-002,
14 of 17 patients (82%) were reported to have a normal
platelet count. In study C08-003, platelet count normal-
isation occurred in 18 of 20 (90%) patients.
In study C08-002, 15 of 17 patients (88%) achieved
thrombotic microangiopathy (TMA) event-free status,
while in study C08-003, 80% of patients achieved TMA
event-free status (deﬁned as ≥12 weeks of stable platelet
count, no PE/PI and no new dialysis). In studies C08-002
and C08-003, the daily median TMA intervention rate,
deﬁned as the number of PE or PI interventions and
number of new dialyses required per patient per day, mea-
sured from pre-eculizumab to study endpoint was signiﬁ-
cantly different (p<0.0001). Both studies C08-002 and
C08-003 reported chronic kidney disease (CKD) improve-
ment by ≥1 stage. In study C08-002, 10 of 17 patients
(59%) showed improvement. In study C08-003, 7 of 20
patients (35%) showed improvement in kidney function.
The median estimated glomerular ﬁltration rate (eGFR)
change at 26 weeks was 20 mL/min/1.73 m2 (median
range −1 to 98) in study C08-002. In study C08-003, the
median change in eGFR was 5 mL/min/1.73 m2 (median
range −1 to 20). Improvement in eGFR of ≥15 mL/min
was observed in 9 of 17 patients (53%) in study C08-002
and only one patient (5%) in study C08-003.
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In study C08-002, haemoglobin level improved in 11
of 17 (65%) patients, although three patients did
receive erythropoiesis stimulating agent (ESA) prior to
receiving eculizumab. In study C08-003, 9 of 20 (45%)
patients showed improvement in haemoglobin; however,
eight patients received ESA which was discontinued in
three patients during eculizumab therapy. In study
C08-002, complete TMA response, (deﬁned as haemato-
logical normalisation, and a ≥25% reduction in serum
creatinine sustained in ≥2 consecutive measurements
for ≥4 weeks) occurred in 11 of 17 patients (65%); in
C08-003, 25% (5/20) of patients achieved a complete
TMA response. No deaths occurred in the two prospect-
ive studies at a median follow-up period of 64 weeks
(study C08-002) and 62 weeks (study C08-003).
Follow-up data week 40, and median week 114
(study C08-003)
Nineteen patients continued into the extension phase
and data analysis was reported on 19 patients using an
intention-to-treat (ITT) design.40 41 At week 40, 16 of 20
patients (80%) remained TMA event free during eculi-
zumab treatment. By median follow-up at 114 weeks, the
19 patients that continued eculizumab treatment
remained TMA event free (95%). TMA intervention rate
was signiﬁcantly different (p<0.001) from baseline at
week 40. Improvement in CKD stage was maintained in
7 of 19 patients (35%) achieving ≥1 CKD stage improve-
ment at week 40, and this had increased to 60% (12/19)
by median 114 weeks. Quality of life (QoL; EuroQoL 5D
score) was signiﬁcantly improved (p<0.0001) at week 40
with 73% achieving a minimally important difference in
QoL. Further improvements in proteinuria (decrease ≥1
grade) occurred at 114 weeks in 80% (12/15) of
patients; serum creatinine decrease (≥25%) was
achieved in 55% of patients at week 114. The proportion
of patients with improved renal function (eGFR
≥15 mL/min/1.73 m2) increased from 5% (26 weeks) to
40% (114 weeks). The mean eGFR change of 7.1 mL/
min/1.73 m2 by week 96 was signiﬁcantly improved
(p=0.05).
Follow-up data at week 100 (study C08-002)
Thirteen patients entered the extension phase and data
analysis was reported on ITT population (n=17).42 Mean
platelet count was signiﬁcantly improved at 2-year follow-up
with 15 patients (88%) achieving and maintaining a plate-
let count of (≥150×109/L). Haematological normalisation
was seen in 88% of patients. TMA event-free status was also
achieved in 15 patients (88%). Improvements in eGFR
(increase of ≥15 mL/min/1.73 m2) continued by a 2-year
follow-up in 10 of 17 patients (58%). Further improve-
ments in CKD stage (≥1 stage) occurred in 71% of
patients; serum creatinine decrease (≥25%) was achieved
in 75% of patients, and proteinuria decrease by (≥1 grade)
were seen in seven of nine patients. EuroQoL 5D score
remained signiﬁcantly improved (p=0.0001) at 2 years.
Results of study C09-001R
Results for the retrospective study are presented in table 2.31
No paediatric patient required new dialysis during treatment
with eculizumab. Platelet count normalisation was observed
Table 1 Efficacy results of prospective studies C08-002 and C08-003 by week 26
Outcomes C08-002 (n=17) C08-003 (n=20)
Change in platelet count from baseline through 73 (40 to 105) 5 (−17.5 to 28)
Week 26 (×109/L), point estimate (95% CI) p=0.0001 p=0.64
Normalisation of platelet count
All patients, n (%) (95% CI) 14 (82) (57 to 96) 18 (90) (68 to 99)
Patients with abnormal baseline, n (%) 13/15 (87%) 3/20 (15%)
TMA event-free status*, n (%) (95% CI) 15 (88) (64 to 99) 16 (80) (56 to 94)
TMA intervention rate†
Daily pre-eculizumab rate, median (minimum, maximum) 0.88 (0.04, 1.59) 0.23 (0.05, 1.09)
Daily posteculizumab rate, median (minimum, maximum) 0 (0, 0.31) 0
p Value p<0.0001 p<0.0001
CKD improvement by ≥1 stage, n (%) (95% CI) 10 (59) (33 to 82) 7 (35) (15 to 59)
eGFR change mL/min/1.73 m2, median (range) at 26 weeks 20 (−1 to 98) 5 (−1 to 20)
eGFR improvement ≥15 mL/min/1.73 m2, n (%) (95% CI) 9 (53) (28 to 77) 1 (5) (0 to 25)
Change in Hb>20 g/L, n (%) (95% CI) 11 (65) (38 to 86) 9 (45) (23 to 68)
Haematological normalisation‡, n (%) (95% CI) 13 (76) (50 to 93) 18 (90) (68 to 99)
Complete TMA response§, n (%) (95% CI) 11 (65) (38 to 86) 5 (25) (9 to 49)
Death 0 0
*TMA event-free status is ≥12 weeks of stable platelet count, no PE/PI and no new dialysis.
†TMA intervention rate is the number of PE or PI interventions and number of new dialyses required per patient per day.
‡Haematological normalisation is the normal platelet and lactate dehydrogenase levels, ≥2 consecutive measurements and ≥4 weeks apart.
§Complete TMA response is haematological normalisation plus at least a 25% reduction in serum creatinine for a minimum of 4 weeks.
Source: Electronic Medicines Compendium.31
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; PE, plasma exchange; PI, plasma infusion; TMA,
thrombotic microangiopathy.
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for the majority of paediatric patients (14/15), and com-
plete TMA response occurred in almost half of all patients
(7/15). Improvement was observed in the daily TMA inter-
vention rate which was lower during the eculizumab treat-
ment compared with the intervention rate before
eculizumab therapy. In 8 of 15 patients (53%), an improve-
ment in eGFR of (≥15 mL/min/1.73 m2) was observed.
Duration of current severe clinical TMA manifestation
(C09-001R)
Paediatric patients that had a shorter duration of severe
TMA (<2 months) were more likely to achieve complete
TMA response and improvement in eGFR with eculizu-
mab compared with patients with a longer duration
(>2 months) of severe TMA (table 3).31 Platelet count
normalisation and TMA event-free status were similar
between the two times for TMA manifestation.
Death
In the retrospective study C009-001R, two deaths
occurred but the manufacturer did not relate these to
eculizumab treatment. One patient died after carotid
artery surgery due to arterial stenosis. The other patient
died due to graft versus host disease after undergoing
bone marrow transplantation.
Adverse events reported within study C08-002
and study C08-003
Hypertension and upper respiratory tract infection were
the most frequently reported adverse events in the two
prospective studies (table 4).34 Headache and diarrhoea
were also frequent problems experienced by patients.
Leucopenia affected 16% of patients, although no
reports of life-threatening infections occurred during
the study phase.
Adverse events reported within study C09-001R
Fever and diarrhoea were the most frequently recorded
adverse events in the retrospective study (table 5).34
Upper respiratory tract infections were also common
with 32% patients reporting this adverse event while
receiving eculizumab.
DISCUSSION
Results from the two prospective single arm studies com-
paring pre-eculizumab baseline measures with follow-up
at 26 weeks showed TMA event-free status was achieved
by 88% of patients in study C08-002 and 80% in study
C08-003. Both prospective studies reported a statistically
signiﬁcant improvement in TMA intervention rate by
the end of the study period (p<0.0001). CKD stage
improvement by ≥1 stages was observed in both pro-
spective studies, and median change in eGFR occurred
in both studies (20 mL/min/1.73 m2 in study C08-002,
and 5 mL/min/1.73 m2 in study C08-003). QoL scores
were signiﬁcantly improved in the short and long term.
Table 3 Results in paediatric patients (C09-001R)
according to duration of current severe clinical TMA
manifestation
Duration of current severe
clinical TMA manifestation
<2 months,
N=10 (%)
>2 months,
N=5 (%)
Platelet count
normalisation
9 (90) 5 (100)
TMA event-free status* 8 (80) 3 (60)
Complete TMA
response†
7 (70) 0
eGFR improvement
≥15 mL/min/1.73 m2
7 (70) 0‡
*TMA event-free status is ≥12 weeks of stable platelet count, no
PE/PI and no new dialysis.
†Complete TMA response is haematological normalisation plus at
least a 25% reduction in serum creatinine for a minimum of
4 weeks.
‡One patient achieved eGFR improvement after renal transplant.
Source: Electronic Medicines Compendium.31
eGFR, estimated glomerular filtration rate; PE, plasma exchange;
PI, plasma infusion; TMA, thrombotic microangiopathy.
Table 2 Efficacy results in paediatric patients enroled in aHUS (C009–001R)
Efficacy parameters
Patients <2 years
(n=5)
Patients 2 to <12 years
(n=10)
Patients <12 years
(n=15)
Requiring new dialysis 0 0 0
Patients with platelet count normalisation, n (%) 4/5 (80) 10/10 (100) 14/15 (93)
Complete TMA response*, n (%) 2/5 (40) 5/10 (50) 7/15 (50)
Daily TMA intervention rate†, median (range)
Before eculizumab 1 (0, 2) <1 (0.07, 1.46) <1 (0, 2)
On eculizumab treatment <1 (0, <1) 0 (0, <1) 0 (0, <1)
Patients with eGFR improvement ≥15 mL/min/
1.73 m2, n (%)
2/5 (40) 6/10 (60) 8/15 (53)
*Complete TMA response is haematological normalisation plus at least a 25% reduction in serum creatinine for a minimum of 4 weeks.
†TMA intervention rate is the number of plasma exchange or plasma infusion interventions and the number of new dialyses required per
patient per day.
Source: Electronic Medicines Compendium.31
aHUS, atypical haemolytic uraemic syndrome; eGFR, estimated glomerular filtration rate; TMA, thrombotic microangiopathy.
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No deaths were reported during the study period or
during the study extension phase in both prospective
studies. The 40 and 114-week follow-up data (C08-003)
indicated that this improvement was maintained. In the
retrospective study (C09-001R), none of the paediatric
patients needed new dialysis during treatment with eculi-
zumab, and platelet count normalisation was observed
in 14 of the 15 patients in this uncontrolled study.
Additional analysis suggested that patients treated with
eculizumab by <2 months had a better response to treat-
ment. The maintenance of the beneﬁcial effects of eculi-
zumab over time in the aHUS trial is consistent with the
experience of 195 PNH patients over 66 months on ecu-
lizumab. There were no treatment-related deaths and
treatment was well tolerated with no evidence for cumu-
lative toxicity and a decreasing occurrence of adverse
effects over time. Importantly, PNH patients also showed
a time-dependent improvement in renal function with
93.1% of patients showing improvement or stabilisation
of a CKD score at 36 months.43
Thus, overall, eculizumab appears to be a highly
effective treatment for aHUS, although it was not com-
pared head to head with optimal plasmapheresis
(current best practice in the UK). However, the absence
of the requirement for new dialysis or deaths over
114-week follow-up in C08-002 suggests that the outcome
for eculizumab is signiﬁcantly better than that recently
Table 4 Patient incidence of adverse events reported in at least 10% of patients (US Food and Drug Administration (FDA))
C08-002 (n=17) C08-003 (n=20) Total (n=37)
Hypertension* 8 (47) 5 (25) 13 (35)
Infections and infestations
Upper respiratory tract infection† 5 (29) 8 (40) 13(35)
Urinary tract infection 4 (24) 2 (10) 6 (16)
Gastrointestinal disorders
Diarrhoea 6 (35) 6 (30) 12 (32)
Vomiting 5 (29) 3 (15) 8 (22)
Nausea 4 (24) 3 (15) 7 (19)
Abdominal pain 0 4 (20) 4 (11)
Nervous system disorders
Headache 7 (41) 4 (20) 11 (30)
Blood and lymphatic system disorders
Anaemia 6 (35) 3 (15) 9 (24)
Leucopenia 4 (24) 2 (10) 6 (16)
Psychiatric disorders
Insomnia 4 (24) 1 (5) 5 (14)
Respiratory, thoracic and mediastinal disorders
Cough 2 (12) 3 (15) 5 (14)
Pharyngolaryngeal pain 1 (6) 4 (20) 5 (14)
General disorders and administration site conditions
Fatigue 3 (18) 1 (5) 4 (11)
Peripheral oedema 3 (18) 1 (5) 4 (11)
Fever 3 (18) 1 (5) 4 (11)
Ear and labyrinth disorders
Vertigo 1 (6) 3 (15) 4 (11)
Musculoskeletal and connective tissue disorders
Pain in extremity 1 (6) 3 (15) 4 (11)
*Includes the preferred terms hypertension, accelerated hypertension and malignant hypertension.
†Includes the preferred terms upper respiratory tract infection and nasopharyngitis.
Source: US FDA.34
Table 5 Adverse reactions occurring in at least 15% of
patients less than 18 years of age enrolled in aHUS study
C09-001R
<2 years
(n=5)
2 to
<12 years
(n=10)
12 to
<18 years
(n=4)
Total
(n=19)
Fever 4 (80) 4 (60) 1 (25) 9 (47)
Diarrhoea 1 (20) 4 (40) 1 (25) 6 (32)
Vomiting 2 (40) 1 (10) 1 (25) 4 (21)
Upper
respiratory
tract
infection*
2 (40) 3 (30) 1 (25) 6 (32)
Cough 3 (60) 2 (20) 0 (0) 5 (26)
Nasal
congestion
2 (40) 2 (20) 0 (0) 4 (21)
Tachycardia 2 (40) 2 (20) 0 (0) 4 (21)
*Includes the preferred terms upper respiratory tract infection and
nasopharyngitis.
Source: US FDA.34
aHUS, atypical haemolytic uraemic syndrome; FDA, Food and
Drug Administration.
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reported for aHUS treated with plasmapheresis alone in
adults with respect to rates of death (0.8%) or ESRD
(46% at 1 year).7 Likewise, the absence of death, lack of
need for new dialysis and improvement in eGFR in the
children treated in the retrospective trial C009-001R is
encouraging given previous reports of 1-year mortality of
6.7% and ESRD rate of 16%.7 However, there are some
indications for caution with a longer term use of eculizu-
mab. First, erythrocytes and platelets have extensive iC3b
and C3d deposited on them through opsonisation, fol-
lowing inhibition of complement at the C5 level. This
can shorten their half-life with increased clearance
through the reticuloendothelial system and has led to
recurrent anaemia and transfusion requirement in some
patients with PNH.44 45 Second, renal biopsy performed
in three patients with either dense deposit disease or C3
glomerulopathy before and after eculizumab treatment46
all showed no signiﬁcant reduction in C3 or C5b-9 stain-
ing and de novo monoclonal staining for IgGκ in the
same distribution as C3 and C5b-9, mimicking monoclo-
nal immunoglobulin deposition disease on post-
treatment biopsies. Staining of the γ heavy chain was
restricted to the IgG2 and IgG4 subclasses, suggesting
binding of the monoclonal eculizumab to C5 in renal
tissue. The long-term effects of this drug–tissue inter-
action are not known.
Most orphan drugs submitted for regulatory approval
are based on RCTs that follow generally accepted rules
and guidance.47 However, randomising patients with
ultra-orphan diseases such as aHUS may be impractical
due to the difﬁculty of recruiting sufﬁcient patients, and
because the risk of disease progression or death is very
high in this population ethical considerations may
prevent the use of RCTs, or patient withdrawal studies.
Therefore, transparent reporting of patient recruitment
and selection are needed to inform decision makers if
the ﬁndings are applicable to all patients with aHUS.
Results may not be generalisable to non-specialist
centres and non-expert use. The limitations of the pro-
spective studies are that the average age of patients was
28 years with an age range of 13–68 years. A more repre-
sentative sample would have included a paediatric popu-
lation to reﬂect this important group of patients with
the disease. Owing to the absence of a control group,
inference of treatment effects may be confounded and it
remains uncertain whether all patients would respond to
eculizumab or even require treatment as reports indicate
that some patients with aHUS, for example, those with
CD46 mutations, experience natural recovery without
any therapy.48 There is also potential for publication
bias in evaluating the retrospective study. The initial two
case reports of treatment of aHUS with eculizumab were
published in the N Engl J Med in 200949 50 and have
been followed by numerous other positive case reports
which have contributed signiﬁcantly to the ﬁeld in
informing best use of eculizumab.22 51 However, it is less
clear if negative data would be similarly published.
Second, the case reports which preceded the prospective
trials by 4 years have the potential for skewing percep-
tion in the ﬁeld. An example of this may exist with
extrapolation of use of eculizumab to Stx-HUS. Here,
despite an initial case report suggesting a beneﬁt of ecu-
lizumab in three children with Escherichia coli
O157-mediated Stx-HUS,52 the summary of results from
a large subgroup of adults affected with E coli
O104-mediated Stx-HUS (n=491)53 54 was that eculizu-
mab and PE (n=193) offered no additional advantage
compared to PE (n=241) or to best practice supportive
care alone (n=57) in a non-randomised trial, where the
most severely affected adult patients received eculizumab
in addition to PE. It is therefore necessary to examine
this question in a formal RCT looking at children and
adults diagnosed with Stx-HUS.
The lack of use of an RCT for aHUS may also be ques-
tionable despite the caveats regarding recruitment with
orphan diseases. The 20 patients in trial C08-003 on
chronic plasmapheresis were all removed from treatment
and converted to eculizumab. It would have been pos-
sible to perform a prospective randomised crossover
trial with these patients in two groups of 10 which would
have yielded useful information. For example, a recent
double blind placebo controlled crossover trial per-
formed in 14 patients with myasthenia gravis showed
that 6 of 7 patients treated with eculizumab for 16 weeks
(86%) achieved the primary end point of a three-point
reduction in Quantitative Myasthenia Gravis (QMG)
score. When both treatment periods were examined,
overall change in mean QMG score was signiﬁcantly dif-
ferent between eculizumab and placebo (p<0.0001).55
Complete reporting is needed in orphan diseases to
facilitate the evaluation of the clinical and cost effective-
ness of treatment and provide clinicians and policy
makers with sufﬁcient evidence to make informed deci-
sions. Establishing global patient registries, or utilising
data from the International Registry of Recurrent and
Familial HUS established in Italy3 would provide insights
into the natural history of this rare disease. Long-term
follow-up data need to be made available for all out-
comes. Many outcomes were biological markers. Ideally,
where surrogate outcomes are substituted for clinical
endpoints in order to predict clinical beneﬁt, these
should be validated to demonstrate the relationship
between surrogate and patient-related outcome.56
The safety data indicated that adverse events in the
uncontrolled prospective studies are frequent, with
hypertension and upper respiratory tract infection affect-
ing about a third of patients, though it remains unclear if
these are treatment-related or complications of aHUS.
The potentially serious complication of leucopenia
affected 16% of patients, although no serious meningo-
coccal infections were reported in the ﬁrst phase or
follow-up period. Only adverse events occurring in at
least 10% of patients were reported and therefore, rare
but serious complications of treatment could remain
unreported. In the retrospective study C09-001R, adverse
events were only reported using a higher threshold of
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≥15% of patients. Fever was a frequently reported
adverse event in 47% of patients. Upper respiratory tract
infection and diarrhoea affected about a third of patients.
One case of meningococcal infection was reported in a
patient with aHUS, which occurred in study C09-001R
after the data cut-off period. The patient fully recovered
and remained on eculizumab. Thus, the safety data in
the short-term treatment of aHUS is reassuring. However,
risks of meningococcal sepsis remain throughout treat-
ment duration because late complement pathway deﬁ-
ciencies predispose to meningococcal infections by the
absence of meningococcal lysis through classical and
alternative pathways.57 Consequently, protection against
meningococcal disease by antibody-mediated killing
becomes essential. All patients need to be vaccinated
against Neisseria meningitidis and many physicians also
provide antibiotic prophylaxis, for example with cipro-
ﬂoxacin58 as the commonest European meningococcal
serotype, (type B), is not included in the tetravalent
vaccine. Patient education about this potential complica-
tion on eculizumab treatment will be critical to facilitate
rapid treatment with appropriate antibiotics as soon as
there is any suspicion of meningococcal disease. Levels of
side effect monitoring and awareness of meningococcus
are very high within trials but may not be maintained
outside trial settings.
Poor response to meningococcal vaccination has
been reported in two patients with renal transplants on
immunosuppression, one of whom developed meningo-
coccal septicaemia which responded to prompt resusci-
tation and empiric antibiotic treatment.58 Subsequent
repeat vaccination, including a different conjugate
vaccine preparation, also failed to induce immunity.58 A
further transplant patient had waning but protective
titres to meningococcus C vaccination.59 Therefore, if
eculizumab becomes used more widely to facilitate
renal transplantation for patients with underlying
aHUS, there needs to be an awareness of the potential
for complication by meningococcal disease despite
prior vaccination. Also, the efﬁcacy of vaccination in
eculizumab-treated patients receiving immunosuppres-
sive therapy cannot be assumed. Patients should prefer-
ably be vaccinated before receiving immunosuppressive
therapy. The trial data may also not be extrapolatable
to proposed use of eculizumab to facilitate de novo
transplantation in those patients with aHUS established
long term on dialysis. Patients on dialysis have poor
response to vaccinations, for example, failed seroconver-
sion and loss of immunity with time after hepatitis B
vaccination.60
Following completion of the systematic review, the
Advisory Group for National Specialised Services in the
UK has advised government ministers that there is evi-
dence of clinical effectiveness for the treatment of
aHUS; ministers have since requested further data on its
affordability61 and ﬁndings are expected to be reported
by the National Institute for Health and Care Excellence
(NICE) at the end of 2013.
CONCLUSIONS
The results from three, small, uncontrolled studies indi-
cate that eculizumab is clinically effective in patients
with aHUS and reduces TMA activity as measured by
TMA event-free status, and normalises platelet count in
the majority of patients. No severe life-threatening
adverse events were associated with treatment. Study
extension results suggest the beneﬁts of treatment are
sustained. However, due to the study design limitations,
inference of treatment effects may be confounded by
the lack of a control group.
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